Chief Operating Officer

Associate Director Regulatory Affairs Labeling

argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025

Argenx price target raised by $55 at BofA, here's why

Sjögren’s Disease Remains an Underdiagnosed and Underguided Condition, Creating an Opening for Manufacturers to Shape the Future of Care, According to Spherix Global Insights

argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session

Associate Director, US HCP Marketing – MG

argenx is a global immunology company focused on developing antibody-based medicines for patients with severe autoimmune diseases. The Associate Director, US HCP Marketing – MG will be responsible for shaping media strategy and leading the execution of campaigns to engage healthcare professionals, supporting the VYVGART brand and its indications.

Sign up with Google

Sign in with Google